Leading-edge CRISPR biotech chooses FSHD as its first disease target Epic Bio, based in the San Francisco Bay Area, announced that FSHD is the first disease it plans to take… Read More »
Epic Bio takes aim at DUX4
Roche announces Phase 2 trial in FSHD
The drug, GYM329, aims to boost muscle growth Roche, the Swiss pharmaceutical giant, has announced that it is launching an international Phase 2 clinical trial for facioscapulohumeral muscular dystrophy (FSHD)…. Read More »
Sanofi and miRecule to partner on FSHD drug program
Bringing two technologies together for a best-in-class therapy miRecule, Inc., a biotech based in Gaithersburg, Maryland, today announced a strategic collaboration and exclusive license agreement with pharmaceutical giant Sanofi to… Read More »
SOLVE FSHD Invests US $1 Million in miRecule
Funds aim to accelerate development of best-in-class antibody-RNA conjugate to treat facioscapulohumeral muscular dystrophy GAITHERSBURG, Maryland and VANCOUVER, British Columbia – September 29, 2022 (View original source.) – miRecule, Inc.,… Read More »
Avidity Biosciences announces Phase 1/2 trial for FSHD
Trial has FDA approval. Start dates and locations have not yet been determined. San Diego-based Avidity Biosciences announced this morning that it plans to launch a Phase 1/2 clinical trial… Read More »